Inactive Instrument

Press Releases SciSparc Ltd. OTC Markets

Equities

TRPXD

US80909J1025

Press Releases

Unlock all the news: Be the first to know and act before the market!

SciSparc Secures Strategic Advantage with Grant of European Patent	05-31	GL
SciSparc to Acquire AutoMax	04-11	GL
SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research	03-21	GL
SciSparc Granted Another Patent, Strengthening its Core Technology in Canada	03-18	GL
SciSparc Granted Another Patent, Strengthening its Core Technology in Canada	03-18	AQ
SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial	03-14	GL
SciSparc : MitoCareX Update - Form 6-K	03-13	PU
SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure	03-12	GL
SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure	03-12	AQ
SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder	03-08	GL
SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder	03-08	AQ
SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe	03-07	GL
SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe	03-07	AQ
SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology	03-06	GL
SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing	02-29	GL
SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing	02-29	AQ
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds	02-27	GL
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds	02-27	AQ
Clearmind Medicine Submits Three International Patent Applications for Next Generation Classical Psychedelic-Based Compounds	02-21	AQ
SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds	02-20	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases SciSparc Ltd. OTC Markets

Equities

TRPXD

US80909J1025

Press Releases

Filters